ClearPoint Neuro, Inc. CLPT
At closeNov 3, 2026, 4:28 PM EST
After hours · Nov 3, 4:28 PM ET
- YTD
- -29.02%
- 1 year
- -48.89%
- Market cap
- 311.25M
- Revenue (ttm)
- 30.43M
- Profit margin
- -59.64%
- EPS (ttm)
- -1.21
- Shares out
- 27.58M
- Forward P/E
- -23.98
- YTD return
- -29.02%
- 1-year return
- -48.89%
- Volume
- 784.04K
- Avg volume
- 683.13K
- Open
- 10.01
- Previous close
- 9.95
- Day's range
- 9.53 – 10.18
- 52-week range
- 8.27 – 19.63
- Beta
- 1.11
- Analysts
- Strong Buy
- Price target
- 17.00 (+75.1%)
- Earnings date
- Aug 7, 2024
2Y -3.02 (-23.70%)
Key statistics
- Enterprise value
- 410.93M
- PEG ratio
- 0.00
- Price / sales
- 13.26
- Price / book
- 13.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 41.00%
- Free cash flow
- -1.29M
- Total cash
- 21.57M
- Total debt
- 3.69M
- Return on equity
- -68.36%
- Short % of float
- 2.74%
- 50-day average
- 12.91
- 200-day average
- 9.07
Analyst view
Consensus: strong buy
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.16333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.17 | -0.18 | -0.01 | -5.88% |
| Aug 7, 2024 | Jun 1, 2024 | -0.19 | -0.16 | +0.03 | +15.79% |
| Aug 7, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.19 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.19 | -0.16 | +0.03 | +15.79% |
| Mar 12, 2024 | Dec 1, 2023 | -0.22 | -0.19 | +0.03 | +13.64% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2024 | Lake Street | main | Buy | Buy |
| Mar 13, 2024 | Stifel | reit | Buy | Buy |
| Oct 24, 2023 | Stifel | init | — | Buy |
| Aug 9, 2023 | Lake Street | main | Buy | Buy |
| Mar 18, 2021 | Lake Street | init | — | Buy |
| Jul 17, 2020 | B. Riley Securities | init | — | Buy |
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- clearpointneuro.com
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT 
Stifel Maintains Buy on ClearPoint Neuro, Lowers Price Target to $18 
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call 
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates 
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript 
ClearPoint Neuro Q3 2026 Earnings Call Transcript 
ClearPoint Neuro Narrows FY2026 Sales Guidance from $48.000M-$52.000M to $48.000M-$50.000M vs $49.000M Est 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Your note
Sign in to keep a note on CLPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNETT JOSEPH MICHAEL | Chief Executive Officer | Stock Award(Grant) | Jun 27, 2024 | 252,861 |
| D'ALESSANDRO DANILO | Chief Financial Officer | Stock Award(Grant) | Jun 27, 2024 | 50,683 |
| FALLON LYNNETTE C | Director | Conversion of Exercise of derivative security | May 13, 2024 | 30,008 |
| FLETCHER R JOHN | Director | Stock Award(Grant) | Sep 30, 2024 | 93,537 |
| GIRIN PASCAL E R | Director | Stock Award(Grant) | Sep 30, 2024 | 74,087 |
| JOHNSON B KRISTINE | Director | Conversion of Exercise of derivative security | May 13, 2024 | 37,606 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.51% | 1,242,993 | 18.18M | Sep 29, 2024 |
| Essex Investment Management Co LLC | 1.68% | 463,853 | 6.79M | Sep 29, 2024 |
| Taylor Frigon Capital Management LLC | 1.36% | 374,797 | 5.48M | Sep 29, 2024 |
| Blackrock Inc. | 1.35% | 371,601 | 5.44M | Sep 29, 2024 |
| Brown Advisory Inc. | 1.21% | 333,395 | 4.88M | Sep 29, 2024 |
| CM Management, LLC | 1.09% | 300,000 | 4.39M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.92% | 804,249 | 11.77M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.43% | 393,527 | 5.76M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.53% | 146,887 | 2.15M | Oct 30, 2024 |
| PFS Funds-Taylor Frigon Core Growth Fund | 0.32% | 88,829 | 1.30M | Aug 30, 2024 |
| 1290 Fds-1290 Essex Small Cap Growth Fd | 0.31% | 85,936 | 1.26M | Jul 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.24% | 66,992 | 980.09K | Sep 29, 2024 |